电话:
400-7060-959
传真:
+86 10 56315212-8813
电子邮件:
orders@antibodies-online.cn

Biosimilar Antibodies

Biosimilar antibodies have emerged as valuable tools for research purposes. These antibodies, derived from genetically engineered cells, mimic the structure and function of existing therapeutic antibodies, offering cost-effective alternatives for research applications. With advancements in recombinant DNA technology and protein expression systems, monoclonal biosimilar antibodies can be produced with high specificity and reproducibility, providing researchers with reliable reagents for various experiments. The availability of recombinant biosimilar research antibodies broadens the accessibility of research-grade antibodies, facilitating scientific investigations and accelerating discoveries in diverse fields, from basic biological research to drug development and diagnostics. Discover recombinant biosimilar antibodies from antibodies-online.com.

Biosimilar Research Antibodies for Top Selling Biologicals

Below you may find the main indications, mechanisms and matching monoclonal biosimilar research antibodies for the top selling biologicals:

  1. Adalimumab
    • Therapeutic Indications: Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, and others.
    • Mechanism: TNF-alpha inhibitor.
    • Biosimilar Research Antibody: Adalimumab Biosimilar Research Antibody
  2. Rituximab
    • Therapeutic Indications: Non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis.
    • Mechanism: Monoclonal antibody targeting CD20 antigen.
    • Biosimilar Research Antibody: Rituximab Biosimilar Research Antibody
  3. Trastuzumab
  4. Pembrolizumab
    • Therapeutic Indications: Various cancers, including melanoma, lung cancer, and others.
    • Mechanism: Immune checkpoint inhibitor (PD-1 inhibitor).
    • Biosimilar Research Antibody: Trastuzumab Biosimilar Research Antibody
  5. Enbrel
    • Therapeutic Indications: Rheumatoid arthritis, psoriasis, ankylosing spondylitis, and others.
    • Mechanism: TNF-alpha inhibitor.
    • Biosimilar Research Antibody:
  6. Infliximab
    • Therapeutic Indications: Rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, ankylosing spondylitis.
    • Mechanism: TNF-alpha inhibitor.
    • Biosimilar Research Antibody: Infliximab Biosimilar Research Antibody
  7. Bevacizumab
  8. Aflibercept
    • Therapeutic Indications: Age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion.
    • Mechanism: VEGF inhibitor.
    • Biosimilar Research Antibody: Aflibercept Biosimilar Research Antibody
  9. Nivolumab
    • Therapeutic Indications: Various cancers, including melanoma, lung cancer, and others.
    • Mechanism: Immune checkpoint inhibitor (PD-1 inhibitor).
    • Biosimilar Research Antibody: Nivolumab Biosimilar Research Antibody
  10. Daratumumab

Case Study: Assessing Binding Affinity of Adalimumab Biosimilar

SPR analysis of adalimumab and its binding partners. Immobilized antibody molecules produced from either BYL or CHO cells were probed with recombinant TNFa and CD64 to show ligand and receptor binding, respectively.

Biosimilar Antibody used as benchmark: Recombinant TNF Alpha Antibody (ABIN5668145) .

Source: Biotech & Bioengineering, First published: 28 June 2023, DOI: (10.1002/bit.28461)

Case Study: Assessing Binding Affinity of Adalimumab Biosimilar

Biosimilar Antibodies in Drug Discovery

In drug discovery and subsequent development phases, biosimilar antibodies like Infliximab can be used as benchmarks in several ways:

  • Analytical Methods and Characterization: Molecular structure, post-translational modifications (PTMs), binding-specifities, and other attributes of approved biologicals are well-characterized due to their history as a reference biologic. Analytical methods and characterization techniques for new biosimilars or alternative therapy approaches can be benchmarked against those used for existing biosimilars to ensure accurate assessment of similarity.
  • Pharmacokinetics: Biosimilars can provide a reference point for comparing the pharmacokinetic properties of a biosimilar to those of the reference product. Pharmacokinetics refers to the study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Immunogenicity Assessment: Immunogenicity profiles, or the likelihood of triggering an immune response, are known from clinical experience for biosimilars that have already been introduced to the market. When developing a biosimilar or an alternative therapeutic approach, companies benchmark their immunogenicity assessment strategies against those used for existing biosimilars to ensure appropriate evaluation of potential immune reactions.
  • Clinical Trial Design: Clinical trials for biosimilar development often include a comparative efficacy and safety study, where the biosimilar is compared to the established reference product (e.g. Trastuzumab). The clinical trial design, endpoints, patient populations, and statistical analyses are often compared to existing trials of the reference product.
  • Regulatory Approval Pathways: Regulatory authorities, such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), use approved biosimilars (e.g. Ranibizumab) as a reference when establishing guidelines and requirements for biosimilar approval. Developers of biosimilars can adapt their development processes and compare their data against the regulatory expectations set for existing biosimilars.

Overall, biosimilars that are already in the clinic have a well-established history, clinical data, and regulatory status that make them valuable benchmarks in drug discovery to demonstrate the similarity, safety, and effectiveness of new drug candidates. Established and well studied biosimilars serve as gold standard when establishing new biological drugs and treatments. antibodies-online.com offers a very broad range of biosimilars and a great product range to choose from.

Explore all Biosimilar Research Antibodies

537 results :

适用: Cynomolgus, 人, 猕猴 BP, FACS, IP 宿主: 兔 Monoclonal hL22 unconjugated Recombinant Antibody
产品编号 ABIN5668217
适用: 人, Cynomolgus, 猕猴 FACS 宿主: 兔 Monoclonal 10F381 unconjugated Recombinant Antibody
产品编号 ABIN5668183
适用: 人, Cynomolgus, 猕猴 BR, FACS 宿主: 兔 Monoclonal unconjugated Recombinant Antibody
产品编号 ABIN5668119
适用: 人, Cynomolgus, 猕猴 FACS, BR, IF, IHC, WB 宿主: 兔 Chimeric unconjugated Recombinant Antibody
产品编号 ABIN5668051
适用: 人 BI, FACS, IHC 宿主: 小鼠 Monoclonal B72-3 unconjugated Recombinant Antibody
产品编号 ABIN5668023
适用: 人, Cynomolgus, 猕猴 FACS, BR, IF, IHC, WB 宿主: Human Chimeric unconjugated Recombinant Antibody
产品编号 ABIN5668050
适用: 人 BR, FACS, WB 宿主: Human Monoclonal unconjugated Recombinant Antibody
产品编号 ABIN5668060
Research Grade 适用: 人 ELISA, FACS 宿主: Humanized Monoclonal unconjugated Recombinant Antibody
产品编号 ABIN6964436
适用: 人, Cynomolgus, 猕猴 BR, FACS 宿主: Human Monoclonal unconjugated Recombinant Antibody
产品编号 ABIN5668118
适用: 人 FACS, BR 宿主: Human Monoclonal C225 unconjugated Recombinant Antibody
产品编号 ABIN5668058
  • Query: biosimilar
  • 类型 Primary
    • Primary
  • 抗原
    • VEGF (Bevacizumab Biosimilar)
    • EGFR (Cetuximab Biosimilar)
    • ErbB2/Her2 (Trastuzumab Biosimilar)
    • ITGA4 (Natalizumab Biosimilar)
    • MS4A1 (Rituximab Biosimilar)
    • TNF alpha (Adalimumab Biosimilar)
    • CD33 (Gemtuzumab Biosimilar)
    • CD40L (Ruplizumab Biosimilar)
    • EGFR (Matuzumab Biosimilar)
    • IL-6R (Tocilizumab Biosimilar)
    • IL2RA (Basiliximab Biosimilar)
    • IL2RA (Daclizumab Biosimilar)
    • TNF alpha (Infliximab Biosimilar)
    • CD274 (Atezolizumab Biosimilar)
    • CD3E (Muromonab Biosimilar)
    • CD47 (Magrolimab Biosimilar)
    • CD80 (Galiximab Biosimilar)
    • CTLA-4 (Ipilimumab Biosimilar)
    • EGFR (Zalutumumab Biosimilar)
    • GPIIb/IIIa (Abciximab Biosimilar)
    • ITGAL (Efalizumab Biosimilar)
    • PDCD1 (Pembrolizumab Biosimilar)
    • TNF alpha (Humicade Biosimilar)
    • TNFSF11 (Denosumab Biosimilar)
    • TNFSF4 (Oxelumab Biosimilar)
    • 4-1BB (Utomilumab Biosimilar)
    • APP (Aducanumab Biosimilar)
    • AXL (Enapotamab Biosimilar)
    • C5 (Eculizumab Biosimilar)
    • CA9 (Girentuximab Biosimilar)
    • CALCRL (Erenumab Biosimilar)
    • CCL2 (Carlumab Biosimilar)
    • CCN2 (Pamrevlumab Biosimilar)
    • CCR2 (Plozalizumab Biosimilar)
    • CCR4 (Mogamulizumab Biosimilar)
    • CD19 (Inebilizumab Biosimilar)
    • CD22 (Epratuzumab Biosimilar)
    • CD22 (Pinatuzumab Biosimilar)
    • CD27 (Varlilumab Biosimilar)
    • CD274 (Avelumab Biosimilar)
    • CD274 (Durvalumab Biosimilar)
    • CD37 (Naratuximab Biosimilar)
    • CD38 (Daratumumab Biosimilar)
    • CD3E, MS4A1 (Mosunetuzumab Biosimilar)
    • CD4 (Clenoliximab Biosimilar)
    • CD47 (Lemzoparlimab Biosimilar)
    • CD52 (Alemtuzumab Biosimilar)
    • CD70 (Vorsetuzumab Biosimilar)
    • CD79B (Polatuzumab Biosimilar)
    • CEACAM5 (Arcitumomab Biosimilar)
    Please use search to find more...
  • 应用范围
    • ELISA
    • Flow Cytometry (FACS)
    • Western Blotting (WB)
    • Blocking Reagent (BR)
    • In vivo Studies (in vivo)
    • Immunohistochemistry (IHC)
    • Immunofluorescence (IF)
    • Immunoprecipitation (IP)
    • Functional Studies (Func)
    • BioImaging (BI)
    • Blocking Peptide (BP)
    • Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
    • Inhibition Assay (InhA)
    • Radioimmunoassay (RIA)
    • Surface Plasmon Resonance (SPR)
    • Antagonist (Anta)
    • Depletion (Dep)
    • Neutralization (Neut)
  • 适用
    • Human
    • Mouse
    • Cynomolgus
    • Rhesus Monkey
    • Chimpanzee
    • Respiratory Syncytial Virus (RSV)
    • Clostridium difficile
    • Dog
    • Pseudomonas aeruginosa
    • SARS Coronavirus-2 (SARS-CoV-2)
    • Shigella
  • 论文引用
  • 图像
  • Preservative free only
  • 抗体来源
    • Mammalian Cells
    • Human
    • Humanized
    • Mouse
    • Rabbit
    • CHO Cells
    • Humanized Mouse
  • 克隆形成能力
    • Monoclonal
    • Chimeric
  • 克隆
    • 10F381
    • 4D5-8
    • C225
    • CDP 571
    • D2E7
    • R4930
    • cA2
    • hu5c8
    • 2F8
    • 7E3
    • B72-3
    • CE9-1
    • HP67-6
    • IDEC-114
    • IDEC-131
    • M200
    • OKT-3
    • RSHZ19
    • RhPM-1
    • hL22
    • hu1124
    • 5C4-B8
    • H-R3
    • KW-0761
  • 抗原表位
    • Glu239Asp-Mutant
    • Met241Leu-Mutant
    • Extracellular Domain
    • AA 133-285
    • Lys97Arg-Mutant
    • Ser257Ala-Mutant
  • 标记
    • 非结合性
  • 抗体亚型
    • IgG1 kappa
    • IgG1
    • IgG4
    • IgG2
    • IgG4 kappa
    • IgG kappa
    • IgG1 lambda
    • IgG2 kappa
    • IgG2 lambda
    • IgG4 lambda
    • IgG
    • kappa
    • IgG lambda
    • IgG2a kappa
    • IgG2a
    • IgG2b
    • IgM kappa
  • 蛋白类型
    • Recombinant Antibody
  • Format
    • Lyophilized
    • Liquid
  • Fragment
    • Fab fragment
  • Grade
    • Research Grade
  • Supplier
    • ProteoGenix
    • antibodies-online
You are here:
客服